Silence Therapeutics (SLN) Equity Ratio (2018 - 2026)

Silence Therapeutics' Equity Ratio history runs 9 years deep, the most recent figure standing at 0.43 for Q1 2026.

• In Q1 2026, Equity Ratio fell 29.47% year-over-year to 0.43; the TTM figure through Mar 2026 stood at 0.43 (down 29.47% YoY), while the FY2025 annual figure was 0.47, down 28.33% from the prior year.
• Equity Ratio came in at 0.43 for Q1 2026 at Silence Therapeutics, down from 0.47 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.66 in Q4 2024 to a low of 0.13 in Q2 2023.
• A 5-year average of 0.44 and a median of 0.5 in 2025 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio jumped 352.81% in 2024 and decreased 29.47% in 2026, its largest moves.
• Silence Therapeutics' Equity Ratio stood at 0.21 in 2022, then decreased by 11.49% to 0.18 in 2023, then jumped by 263.95% to 0.66 in 2024, then slipped by 28.33% to 0.47 in 2025, then fell by 9.47% to 0.43 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.43, 0.47, and 0.5 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison